Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus paclitaxel and carboplatin for treatment-naive advanced thymic carcinoma
ChiCTR2000039155Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, paclitaxel and carboplatin in thymic carcinoma (TC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Sep 2020; status: recruiting.
02
Drugs
toripalimabpaclitaxelcarboplatin
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2000039155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039155.